Eisai Video Interview AT AAIC Alzheimer's Conference, July 15

Eisai's Michael Irizarry talks to Scrip about broadening Leqembi's use with its subcutaneous version, its ongoing Phase III in treating patients before dementia symptoms appear and news from a Phase II study of it tau-targeting asset, etalanetug.

Episode metadata supplied by the publisher feed · Published Jul 17, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Eisai Video Interview AT AAIC Alzheimer's Conference, July 15

0:00 12:32

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Citeline Podcasts?

This episode is 12 minutes long.

When was this Citeline Podcasts episode published?

This episode was published on July 17, 2026.

Can I download this Citeline Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!